Selecta raises $20M for diabetes and gout immunotherapies

With support from Sanofi and the Juvenile Diabetes Research Foundation, Boston-based Selecta Biosciences has raised $20 million to advance drug candidates for Type 1 diabetes and severe gout. Of the gout program, CEO Werner Cautreels said in a statement: “SEL-212 is just the beginning for us, as we have identified many biopharmaceuticals, including existing and new classes of […]